The FDA today announced a proposed rule that would amend regulations concerning the use of master files for biologics. According to the FDA, this rule is necessary to avoid any disruption to products that will transition from regulation as drugs to regulation as biologics in 2020.
The FDA today announced a proposed rule that would amend regulations concerning the use of master files for biologics. According to the FDA, this rule is necessary to avoid any disruption to products that will transition from regulation as drugs to regulation as biologics in 2020.
The rule applies to products that are currently approved under the Federal Food, Drug, and Cosmetics Act but are slated to be transitioned to licensure under the Public Health Service (PHS) Act in March 2020, and it would allow these products to continue to rely, by reference, on information on a drug substance, drug substance intermediate, or drug product (DS/DSI/DP) that is contained in master files after the products make their transition.
Master files are submissions to the FDA that can be used to provide detailed, confidential information about topics including facilities, processes, or articles used in the manufacturing, processing, packaging, or storage of a product. The information contained in such a file can be used to support a submission by a drug sponsor, and the FDA generally allows Biologics License Applications to incorporate, by reference, information contained in these files.
The holder of such a file can authorize applicants or sponsors to refer to information in the file in their submissions to the FDA without having to disclose that information—such as trade secrets or confidential commercial information—to the applicants or sponsors. Incorporation by reference allows the FDA to review this information in the file in the context of a regulatory application.
The rule also codifies the FDA’s current practice, which allows a biologic product in a Biologics License Application to incorporate by reference information (other than DS/DSI/DP information) contained in a master file. This type of information may be related to excipients, stabilizers, penetrants, or other materials. However, as a scientific matter, the FDA requires applicants to submit information on DS/DSI/DP directly, without relying on a file, in part because biologics have features that can be sensitive to changes in manufacturing processes.
However, the FDA allows the use of DS/DSI/DP information in Investigational New Drug Applications, in part to help facilitate development; the new rule would also codify this practice for products subject to the PHS Act.
The FDA says that, to date, it has identified approximately 89 products that will transition, and approximately 17 of them currently incorporate by reference information on DS/DSI/DP.
The FDA will receive comments on the proposed rule for 60 days after the rule is published in the Federal Register.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.